Published in Cancer Weekly, June 1st, 1998
The data were the basis for the U.S. Food and Drug Administration's (FDA) accelerated approval of Xeloda on April 30, 1998. The product is now available in the United States.
The FDA's decision was based on a subset of 43 patients resistant to paclitaxel and an anthracycline-containing regimen; the response...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.